[go: up one dir, main page]

AR132992A1 - Agonistas de trem2 - Google Patents

Agonistas de trem2

Info

Publication number
AR132992A1
AR132992A1 ARP240101553A ARP240101553A AR132992A1 AR 132992 A1 AR132992 A1 AR 132992A1 AR P240101553 A ARP240101553 A AR P240101553A AR P240101553 A ARP240101553 A AR P240101553A AR 132992 A1 AR132992 A1 AR 132992A1
Authority
AR
Argentina
Prior art keywords
trem2
agonists
compounds
diseases
prevention
Prior art date
Application number
ARP240101553A
Other languages
English (en)
Inventor
Stefan Berchtold
Virginie Brom
Julie Charpentier
Francesco Maria Emilia Di
Guido Galley
Luca Claudio Gobbi
Wolfgang Guba
Roland Johann Humm
Marie Imhoff
- Ohara Fionn Susannah Paule
Anglique Patiny-Adam
Flore Marie Aude Reggiani
Nicolas Zeidan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR132992A1 publication Critical patent/AR132992A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención proporciona compuestos que tienen la fórmula general (1) en donde A¹, A², X¹, X², R¹, R², R³, R⁴ y R⁷ son como se describen en la presente, composiciones que incluyen los compuestos, procesos para elaborar los compuestos y métodos para usar los compuestos en el tratamiento o la prevención de enfermedades que están asociadas con TREM2.
ARP240101553A 2023-06-19 2024-06-18 Agonistas de trem2 AR132992A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23179957 2023-06-19
EP23211237 2023-11-21

Publications (1)

Publication Number Publication Date
AR132992A1 true AR132992A1 (es) 2025-08-13

Family

ID=91621082

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240101553A AR132992A1 (es) 2023-06-19 2024-06-18 Agonistas de trem2

Country Status (3)

Country Link
AR (1) AR132992A1 (es)
TW (1) TW202515878A (es)
WO (1) WO2024260929A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025146477A1 (en) 2024-01-04 2025-07-10 Muna Therapeutics Aps 2-azetidinyl-7-methyl-8-oxo-6-(trifluoromethyl)-7,8-dihydropyrimido[5,4-d]pyrimidine derivatives derivatives as trem2 modulators for the treatment of neurodegenerative diseases
TW202535410A (zh) 2024-01-04 2025-09-16 丹麥商穆納醫療有限責任公司 Ｔｒｅｍ２調節劑

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8318732B2 (en) * 2008-07-02 2012-11-27 Avexa Limited Compounds having antiviral properties
US20250042897A1 (en) * 2021-11-09 2025-02-06 Vigil Neuroscience, Inc. Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

Also Published As

Publication number Publication date
TW202515878A (zh) 2025-04-16
WO2024260929A1 (en) 2024-12-26

Similar Documents

Publication Publication Date Title
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
AR132992A1 (es) Agonistas de trem2
MX2025002975A (es) Compuestos de anillo fusionado
AR126854A1 (es) Compuestos macrocíclicos para el tratamiento de cáncer
PH12021500014A1 (en) Fused ring compounds
CO2019007863A2 (es) Derivados de benzooxazol como inmunomoduladores
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CO2019011762A2 (es) Compuestos que inhiben la proteína mcl-1
MX2018007774A (es) Compuestos heterociclicos como inmunomoduladores.
PE20181045A1 (es) Compuestos utiles como inmunomoduladores
ECSP20018487A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
DOP2019000206A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
BR112019000247A2 (pt) derivados de 1,3-di-hidróxi-fenila úteis como imunomoduladores
JOP20190151B1 (ar) مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان
CL2018002516A1 (es) Inhibidores de mcl-1 indólicos sustituidos.
CR20180541A (es) Inhibidores de bromodominios
CO2021001219A2 (es) Benzimidazoles sustituidos como inhibidores de pad4
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
BR112022005627A2 (pt) Composto de fórmula estrutural i ou um sal do mesmo, composição farmacêutica e uso de um composto
CL2020001107A1 (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3.
CL2022000019A1 (es) Nuevos compuestos heterocíclicos
MX2020013811A (es) Compuestos.
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
MX2023009059A (es) Antagonistas de gpr84 y usos de estos.